GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagonist Therapeutics Inc (NAS:PTGX) » Definitions » Shiller PE Ratio

PTGX (Protagonist Therapeutics) Shiller PE Ratio : (As of Apr. 29, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Protagonist Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Protagonist Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Protagonist Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagonist Therapeutics Shiller PE Ratio Chart

Protagonist Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Protagonist Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Protagonist Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Protagonist Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagonist Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Protagonist Therapeutics's Shiller PE Ratio falls into.


;
;

Protagonist Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Protagonist Therapeutics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Protagonist Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=1.98/133.1571*133.1571
=1.980

Current CPI (Dec. 2024) = 133.1571.

Protagonist Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.458 99.621 -0.612
201506 -0.547 100.684 -0.723
201509 -0.592 100.392 -0.785
201512 -0.940 99.792 -1.254
201603 -2.003 100.470 -2.655
201606 -0.449 101.688 -0.588
201609 -0.870 101.861 -1.137
201612 -0.670 101.863 -0.876
201703 -0.840 102.862 -1.087
201706 -0.890 103.349 -1.147
201709 -0.290 104.136 -0.371
201712 -0.150 104.011 -0.192
201803 -0.360 105.290 -0.455
201806 -0.410 106.317 -0.514
201809 -0.380 106.507 -0.475
201812 -0.570 105.998 -0.716
201903 -0.580 107.251 -0.720
201906 -1.180 108.070 -1.454
201909 -0.610 108.329 -0.750
201912 -0.630 108.420 -0.774
202003 -0.720 108.902 -0.880
202006 -0.590 108.767 -0.722
202009 -0.210 109.815 -0.255
202012 -0.480 109.897 -0.582
202103 -0.540 111.754 -0.643
202106 -0.690 114.631 -0.802
202109 -0.700 115.734 -0.805
202112 -0.770 117.630 -0.872
202203 -0.430 121.301 -0.472
202206 -0.840 125.017 -0.895
202209 -0.640 125.227 -0.681
202212 -0.690 125.222 -0.734
202303 -0.670 127.348 -0.701
202306 -0.680 128.729 -0.703
202309 -0.580 129.860 -0.595
202312 0.440 129.419 0.453
202403 3.260 131.776 3.294
202406 -0.500 132.554 -0.502
202409 -0.540 133.029 -0.541
202412 1.980 133.157 1.980

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Protagonist Therapeutics  (NAS:PTGX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Protagonist Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Protagonist Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagonist Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Executives
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Arturo Md Molina officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Asif Ali officer: Chief Financial Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Patel Dinesh V Ph D director, officer: President and CEO C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Suneel Gupta officer: Chief Development Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lewis T Williams director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Sarah A O'dowd director 3185 LAURELVIEW COURT, FREMONT CA 94538
Harold E Selick director
Bryan Giraudo director 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Donald A. Kalkofen officer: Chief Financial Officer 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
David Y Liu officer: Chief Scientific Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Chaitan Phd Khosla director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard S Shame officer: Chief Medical Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035

Protagonist Therapeutics Headlines

From GuruFocus